Cash Flow Statement (Annual)

LJPC / La Jolla Pharmaceutical Co. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss -3,760 -11,548 -7,737 -17,935 -21,313 -41,912 -78,185 -114,803
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Share Based Compensation 489 254 8,604 12,373 8,992 11,551 14,349 20,776
    Depreciation - 0 0 5 17 347 730 1,268
    Gain Loss On Disposition Of Assets1 - - - 0 0 -16 -75 -199
    Interest Expense Borrowings - - - - - - - -
    Increase Decrease In Operating Capital
      Increase Decrease In Accounts Receivable - - - - - - - -
      Increase Decrease In Inventories And Other Operating Assets - - - - - - - -
      Increase Decrease In Prepaid Deferred Expense And Other Assets -519 -7 -35 18 94 -824 664 1,642
      Increase Decrease In Other Operating Assets - - - 0 0 70 149 -219
      Increase Decrease In Accounts Payable And Accrued Liabilities -231 31 -49 822 -104 2,322 3,600 4,832
      Increase Decrease In Accrued Liabilities And Other Operating Liabilities - - - 80 739 -248 227 -202
      Increase Decrease In Employee Related Liabilities -88 -78 10 56 324 666 987 2,918
      Increase Decrease In Deferred Rent - - - - - 0 124 335
  Net Cash Provided By Used In Operating Activities -3,391 -1,826 -2,135 -4,734 -12,879 -25,183 -58,672 -84,881
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment - - 0 43 258 1,816 2,218 9,194
  Net Cash Provided By Used In Investing Activities - - 0 -43 -258 -1,816 -2,218 -9,194
Net Cash Provided By Used In Financing Activities
  Proceeds From Royalties Financing - - - - - - - -
  Proceeds From Issuance Of Common Stock - - 0 6,751 53,063 104,596 0 117,480
  Proceeds From Stock Options Exercised - 0 0 0 0 315 149 2,693
  Net Cash Provided By Used In Financing Activities 6,003 - 500 10,001 53,063 104,911 149 119,264
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect - - - - - - - -
Cash Cash Equivalents And Short Term Investments
  Cash And Cash Equivalents At Carrying Value - 5,040 3,405 8,629 48,555 126,467 65,726 90,915
  Restricted Cash Current - - - - - - - -
  Restricted Cash Noncurrent - - - - - - - -
  Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - -

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related News Stories

Stocks To Watch: Time To Talk Valuation

2018-09-01 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (298-9)

7 Biotech Stocks Insiders Are Loading Up On

2018-08-22 247wallst
Biotechnology stocks have a reputation for being some of the most speculative, most volatile stocks out there. Investors and would-be investors have to stay alert to avoid getting burned. One encouraging sign in any company is when insiders put their money where their mouth is and buy shares. Lately, some insiders at biotech companies have been doing just that, sometimes taking advantage of share price moves (not to mention buy windows opening up) in the wake of the release of quarterly reports. (24-12)

La Jolla Pharmaceutical Co (LJPC) CEO George Tidmarsh on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
La Jolla Pharmaceutical Co (NASDAQ:LJPC) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET (0-1)

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

2018-07-05 seekingalpha
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-2)

2 Stable and 2 Speculative Biotech Stocks to Buy | InvestorPlace

2018-06-15 investorplace
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)

CUSIP: 503459604